Second-line therapy following osimertinib in metastatic EGFR -mutated non-small cell lung cancer at an academic medical center
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Purpose
FLAURA2 demonstrated that adding chemotherapy to osimertinib improved overall survival compared with osimertinib monotherapy in metastatic epidermal growth factor receptor -mutated ( EGFR -mut) non-small cell lung cancer (NSCLC). Notably, only 60% of patients in the osimertinib monotherapy arm received second-line therapy after discontinuing first-line osimertinib, raising the concern that FLAURA2 did not accurately reflect real-world practices at academic medical centers. We hypothesized that a higher proportion of patients on osimertinib monotherapy receive second-line therapy at academic medical centers in the United States (US).
Patients and Methods
This is a retrospective cohort study of 115 patients with metastatic EGFR -mut NSCLC treated with first-line osimertinib monotherapy at an academic medical center in the US from February 2018 to July 2024. Analyses included Kaplan-Meier survival estimation, the log-rank test, multivariate Cox regression, and the Kruskal-Wallis test.
Results
Most patients were female (74%) and had a history of never-smoking (69%). Fifty percent were Asian, and 93% of patients had adenocarcinoma histology. The median time to treatment failure (TTF) for all patients on first-line osimertinib was 25.3 months (95% CI: 18.6– 37.5). The median TTF was 16.3 months (CI: 13.3–22.0) for TP53 -mutated patients and 42.3 months (CI: 36.9–NA) for TP53 wild-type patients (log-rank test, P < 0.001). Of the 115 total patients, 66 (57.4%) discontinued first-line osimertinib. Of these 66 patients, 26 (39.4%) either died or pursued hospice. Forty (60.6%) of the 66 patients experienced progression of disease and subsequently received second-line therapy.
Conclusions
Only 61% of patients with metastatic EGFR -mut NSCLC received second-line therapy after osimertinib at our institution, confirming that the second-line therapy rates in the control arm of FLAURA2 are similar to practice patterns at our US academic medical center.
